English

Abstract

AIMS: This study aimed to find out the efficacy of single oral dose 150mg of fluconazole in treatment of acute vulvovaginal candidiasis, to evaluate its safety assessment and the clinical and mycological efficacy assessment. MATERIALS AND METHODS: This study is carried out in department of obstetrics and gynaecology Gandhi medical college sultania hospital Bhopal and with the help of microbiology department Gandhi medical college Bhopal over a period of one year. It is a hospital based clinical prospective study. RESULTS: Maximum age incidence was found between 2130years. Mostly patients belonged to low socioeconomic status and were uneducated. Maximum patients were married (98%) and multiparous (92%), nulliparous formed the smallest group (8%). In factors predisposing to candidiasis, contraceptive methods were found to be important in which maximum incidence was found in patients using oral contraception about 32% and 12% of IUCD users were affected. Other factors were antibiotic treatment (5%) and diabetes (2%). Vaginal discharge and pruritis were the two commonest symptoms found. Among the signs vaginal discharge and white plaques was the commonest sign. On follow up visits 88 cases had complete clinical cure and only 6 cases showed failure and 9 recurrences. In mycological assessment maximum 135 cases showed complete cure, 6 were failure and 9 recurrence. In overall results, excellent results were found in 88cases, good in 38 cases, fair in 9 cases and recurrence in 9 cases. Recurrences were mainly due to rectal carriers. CONCLUSION: In conclusion fluconazole was found effective as a systemic single oral dose therapy for acute vulvovaginal candidiasis. It is proved safe in terms of tolerance and preferred by patients. So in view of its favourable patients acceptability and compliance profile, it is considered as a first line therapeutic choice for treatment of women with vaginal candidiasis.